Should you buy Passage Bio stock now?
No, the technical signal for Passage Bio is currently SELL. Passage Bio trades at $4.44 as of 9/2/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.066 with rising momentum (signal: -0.074); RSI is at 45.6 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $15.50 points to 249.1% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Passage Bio stock?
The average analyst price target for Passage Bio is $15.50. The current price is $4.44, which gives an upside of 249.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $13.95 and $17.05.
Is Passage Bio a dividend stock?
No, Passage Bio does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Passage Bio stock?
Passage Bio is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 110.7%, which classifies the stock as Extremely speculative.
Is Passage Bio overvalued?
No, Passage Bio is considered undervalued based on the analyst price target (249.1% upside). Passage Bio has the following valuation ratios: a P/B ratio of 3.1. The analyst price target suggests that the stock is undervalued by 249.1%.
Is Passage Bio overbought?
No, Passage Bio is not overbought. RSI is at 45.6 (neutral zone). The technical indicators show: RSI is at 45.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.4% below the 20-day average (short-term downtrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Passage Bio earnings report?
The date of the next earnings report for Passage Bio has not been published yet. Check the company's investor calendar for updates.
Is Passage Bio shorted?
Yes, Passage Bio is shorted with 5.3% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Passage Bio stock?
Yes, insiders are net buyers of Passage Bio – they are buying more shares than they are selling. Over the last 3 months, insiders have made 1 purchases and 0 sales. On a net basis, 206,227 $ worth of shares were bought. Across the last 20 reported transactions, the split is 7 purchases and 13 sales, with a net 512,236 $ bought. Active buyers include Lynx1 Capital Management LP. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Passage Bio a good stock?
Based on our total score, Passage Bio is rated as a disastrous stock with a total score of 7 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 12/100, Quality: 6/100, Momentum: 3/100. In addition: analysts see 249.1% upside to the price target; technical signal: Strong Sell. Whether Passage Bio is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Passage Bio stock?
The outlook for Passage Bio based on current data: the average analyst price target is $15.50 (+249.1%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Passage Bio stock moving?
Passage Bio is stable right now. The technical indicators show: the price is close to the 20-day average; short interest is 5.3% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Passage Bio go?
The average analyst price target for Passage Bio is $15.50, which corresponds to a potential gain of 249.1% from the current price of $4.44. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Passage Bio fall?
We lack enough history to give a specific floor for Passage Bio. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Passage Bio do?
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Passage Bio as an investment.
Did Passage Bio raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Passage Bio. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Passage Bio making money or losing money?
We have no current profitability data for Passage Bio. See the latest report in the earnings history above.
Can Passage Bio go bankrupt?
The bankruptcy risk of Passage Bio is rated as elevated. Altman Z2 (a model for assessing financial distress) is -100.80 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 67% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Passage Bio have a lot of debt?
No, Passage Bio has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 67%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
